ACADIA Pharmaceuticals Inc.

16.94-0.4300-2.48%Vol 703.00K1Y Perf -55.94%
Sep 24th, 2021 16:00 DELAYED
BID16.94 ASK16.95
Open17.28 Previous Close17.37
Pre-Market- After-Market17.38
 - -  0.44 2.60%
Target Price
25.80 
Analyst Rating
Strong Buy 1.43
Potential %
52.30 
Finscreener Ranking
★★★★     53.96
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★     50.83
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★     51.94
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
3.02 
Earnings Rating
Buy
Market Cap2.72B 
Earnings Date
3rd Nov 2021
Alpha-0.01 Standard Deviation0.16
Beta0.65 

Today's Price Range

16.9417.42

52W Range

15.6857.46

5 Year PE Ratio Range

-18.80-14.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
1.44%
1 Month
-1.40%
3 Months
-35.27%
6 Months
-34.90%
1 Year
-55.94%
3 Years
-20.88%
5 Years
-51.57%
10 Years
1 323.53%

TickerPriceChg.Chg.%
ACAD16.94-0.4300-2.48
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Financial StrengthValueIndustryS&P 500US Markets
6.40
6.80
0.09
0.12
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
95.70
-56.90
-56.10
-406.10
-56.25
RevenueValueIndustryS&P 500US Markets
463.36M
2.88
30.51
178.49
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.30-0.2710.00
Q01 2021-0.53-0.4220.75
Q04 2020-0.48-0.4212.50
Q03 2020-0.38-0.54-42.11
Q02 2020-0.44-0.2738.64
Q01 2020-0.46-0.57-23.91
Q04 2019-0.37-0.348.11
Q03 2019-0.41-0.2929.27
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.263.70Positive
12/2021 QR-0.289.68Positive
12/2021 FY-1.232.38Positive
12/2022 FY-0.90-8.43Negative
Next Report Date3rd Nov 2021
Estimated EPS Next Report-0.26
Estimates Count10
EPS Growth Next 5 Years %-
Volume Overview
Volume703.00K
Shares Outstanding160.64M
Shares Float99.14M
Trades Count8.80K
Dollar Volume60.84M
Avg. Volume1.84M
Avg. Weekly Volume1.10M
Avg. Monthly Volume1.29M
Avg. Quarterly Volume1.57M

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock closed at 16.94 per share at the end of the most recent trading day (a -2.48% change compared to the prior day closing price) with a volume of 704.33K shares and market capitalization of 2.72B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 580 people. ACADIA Pharmaceuticals Inc. CEO is Stephen R. Davis.

The one-year performance of ACADIA Pharmaceuticals Inc. stock is -55.94%, while year-to-date (YTD) performance is -68.31%. ACAD stock has a five-year performance of -51.57%. Its 52-week range is between 15.68 and 57.46, which gives ACAD stock a 52-week price range ratio of 3.02%

ACADIA Pharmaceuticals Inc. currently has a PE ratio of -10.10, a price-to-book (PB) ratio of 4.75, a price-to-sale (PS) ratio of 5.79, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.30%, a ROC of -40.38% and a ROE of -41.40%. The company’s profit margin is -56.25%, its EBITDA margin is -56.10%, and its revenue ttm is $463.36 Million , which makes it $2.88 revenue per share.

Of the last four earnings reports from ACADIA Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.26 for the next earnings report. ACADIA Pharmaceuticals Inc.’s next earnings report date is 03rd Nov 2021.

The consensus rating of Wall Street analysts for ACADIA Pharmaceuticals Inc. is Strong Buy (1.43), with a target price of $25.8, which is +52.30% compared to the current price. The earnings rating for ACADIA Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ACADIA Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ACADIA Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.16, ATR14 : 0.65, CCI20 : 58.48, Chaikin Money Flow : 0.05, MACD : -0.39, Money Flow Index : 55.54, ROC : 2.48, RSI : 46.61, STOCH (14,3) : 68.48, STOCH RSI : 0.68, UO : 60.83, Williams %R : -31.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ACADIA Pharmaceuticals Inc. in the last 12-months were: Austin D. Kim (Option Excercise at a value of $153 825), Austin D. Kim (Sold 12 589 shares of value $558 864 ), Elena Ridloff (Option Excercise at a value of $0), Elena Ridloff (Sold 4 099 shares of value $178 975 ), Michael J. Yang (Option Excercise at a value of $0), Michael J. Yang (Sold 2 367 shares of value $112 813 ), Srdjan Stankovic (Option Excercise at a value of $3 034 632), Srdjan Stankovic (Sold 110 461 shares of value $5 882 272 ), Stephen R. Davis (Option Excercise at a value of $0), Stephen R. Davis (Sold 28 489 shares of value $1 189 814 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (71.43 %)
11 (73.33 %)
9 (64.29 %)
Moderate Buy
2 (14.29 %)
2 (13.33 %)
2 (14.29 %)
Hold
2 (14.29 %)
2 (13.33 %)
3 (21.43 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.43
Strong Buy
1.40
Moderate Buy
1.57

ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

CEO: Stephen R. Davis

Telephone: +1 858 558-2871

Address: 12830 El Camino Real, San Diego 92130, CA, US

Number of employees: 580

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

58%42%

Bearish Bullish

50%50%

TipRanks News for ACAD

News

Stocktwits